1. All Products
  2. LPV 40mg / r 10mg, granules, sachet
Public Pricelist

LPV 40mg / r 10mg, granules, sachet

https://medicalguidelines.msf.org/en/node/433
https://unicat.msf.org/cat/product/75578
STD DORALPVR1G-

Valid Article

Article is intended to be used with children (<12 years) ONLY.
6.4.2.3 - Protease inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AR10
Anatomical Therapeutic Chemical Classification according to WHOCC
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)
https://unicat.msf.org/web/image/product.template/571313/image_1920?unique=2162994

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

LOPINAVIR (LPV) / RITONAVIR (r)

Therapeutic Action

Fixed-dose combination (FDC) of two antiretrovirals, protease inhibitors (PI)

Indications

HIV infection

Lopinavir/Ritonavir combinations may be used as an alternative when Darunavir/Ritonavir cannot be used.

The combination of Darunavir/Ritonavir is the preferred boosted protease inhibitor option for ART when a protease inhibitor is required.

Instructions for use

LPV 40mg / r 10mg, granules, sachet (DORALPVR1G-) is intended for paediatric use:

  • pour the granules into a small amount of breast milk, water or soft foods
  • administer immediately (within a maximum of 2 hours after preparation).

For adults, DRV eq. 400mg base / r 50mg, tablet (DORADRVR45T) is first choice over LPV 100mg / r 25mg and LPV 200mg / r 50mg, tablets.

Storage

Below 25ºC - Protect from sunlight - Protect from humidity